Evaluation of efficacy and safety of a polyherbal Unani formulation in  diabetes mellitus type 2 (Zayābīṭus Sukkari Qism Sāni) - a randomised  controlled clinical study by Ahmad, N et al.
Indian Journal of Traditional Knowledge 
Vol 20(1), January 2021, pp 15-20 
Evaluation of efficacy and safety of a polyherbal Unani formulation in  
diabetes mellitus type 2 (Zayābīṭus Sukkari Qism Sāni) - a randomised  
controlled clinical study 
N Ahmada,*,†, M Nawab,a M H Kazmib & S H Fatimac 
aDepartment of Moalajat (Medicine),  
bDepartment of Ilmul Advia (Pharmacology), cDepartment of Pathology, National Research Institute of Unani Medicine for Skin 
Disorders, Opp. ESI Hospital, A. G. Colony Road, Erragadda, Hyderabad 500 038, Telangana, India 
E-mail: † drnadeemahmad85@gmail.com
Received 23 December 2019; revised 08 October 2020 
Diabetes mellitus type 2 (Zayābīṭus Sukkari Qism Sāni) is a major health concern in 21st century. Despite tremendous 
advances in modern sciences, there is a lack of relatively safe and effective drug for its management.  
The primary objective of this study was to evaluate the efficacy and safety of a polyherbal Unani formulation containing 
Gurmar booti (Gymnema sylvestre), Gilo (Tinospora cordifolia) and Jamun (Syzygium cumini) in the management of Diabetes 
Mellitus Type 2 (DMT2). It was a randomised controlled clinical study conducted on 60 participants of DMT2 inadequately 
controlled by diet and exercise. The test drug was given to group-A participants (n=30) 6 g twice daily orally for 12 weeks and 
the standard drug metformin (500 mg) was given twice daily orally to group-B participants (n=30).  
It was observed that the difference between the Mean (± SD) value of fasting blood glucose (FBG), postprandial blood 
glucose (PPBG) and glycosylated haemoglobin (HbA1c) in Test and Control groups at the end of the study in comparison to 
baseline was significant (p<0.05). This study concludes that the test drug was effective in reducing FBG and PPBG significantly 
in diabetic participants’ at 12 weeks of treatment.  
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Diabetes mellitus type 2 (Zayābīṭus Sukkari Qism 
Sāni) is a major health concern in the 21st century1,2. 
It is defined as a chronic metabolic disorder that 
occurs due to increased glucose levels in the blood 
because the body cannot produce any or sufficient 
insulin hormone or use insulin effectively3,4. As per 
WHO estimates diabetes mellitus type 2 (DM Type 2) 
was the leading cause of death in 2016 globally. Its 
incidence is rapidly rising and reached an epidemic 
like situation worldwide. It was estimated that 425 
million peoples are suffering from diabetes and it is 
supposed that it could reach 629 million by 20452. 
Currently, there are 72.9 million peoples affected by 
diabetes in India5. As per an estimate of WHO, 
1.6 million death were caused by diabetes in 2016. 
Retinopathy, renal failure, heart attack, stroke and 
lower limb amputation are the major complications of 
diabetes mellitus type 2. Healthcare expenditures to 
manage diabetes mellitus and associated disorders 
become a burden for the country. In India, the 
treatment and healthcare cost 31 billion International 
Dollar (ID) to the exchequer6.  
Till this date, there is no cure for this healthcare 
problem. It can be managed by serum glucose level 
with the help of the therapeutics, diets and exercises. 
There are certain identified modifiable risk factors such 
as overweight, obesity, stress, alcohol and smoking. 
Diabetes can be prevented and managed by 
modification of lifestyle and these risk factors. Unani 
system of medicine (USM) offers treatment for 
diabetes mellitus type 2 and other metabolic disorders 
by different treatment modalities such as 
pharmacotherapy, regimen therapy and dietotherapy. 
Many classical prescriptions comprising of single 
herbo-mineral drugs and pharmacopoeial formulations 
have been recommended for the management of 
diabetes mellitus type 2. Preclinical studies conducted 
in the recent past have demonstrated the efficacy of 
Gurmar Booti (Gymnema sylvestre), Gilo Khushk 
(Tinospora cordifolia), Maghz-i-Tukhm Jamun 
(Syzygium cumini), Neem (Azadirachta indica) and 
Karela (Momordica charantia) as hypoglycemic 
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agents. The pharmacopoeial formulations comprising 
of Gurmar Booti (Gymnema sylvestre) Gilo Khushk 
(Tinospora cordifolia) and Maghz-i-Tukhm Jamun 
(Syzygium cumini) has been selected after thorough 
literature survey expecting a promising result7. The aim 
of this study was to record and document the efficacy 
and safety of the Unani formulation in the management 
of diabetes mellitus type 2 which may become a piece 
of evidence that would validate the indication of the 
Unani formulation in the management of diabetes 
mellitus type 2.  
 
Materials and Methods 
The present study was carried out with  
60 participants (30 participants in each group) of 
diabetes mellitus type 2 at outdoor patient department 
of Central Research Institute of Unani Medicine 
(CRIUM), Hyderabad during July 2018-July 2019. 
This study was designed as non-inferior, assessor-
blinded, parallel group, randomized and active 
controlled. The first participant was enrolled  
after Institutional Ethics Committee approval  
(F. No. 22-1/2016/CRIUM/HYD/Tech./04/M) and 
registration of the study in Clinical Trials Registry-
India (CTRI) on 20th December 2017 under 
registration no. CTRI/2017/12/010929.  
The participants with diabetes mellitus type 2 aged 
between 18 years and 65 years of both sexes were 
included in this study based on Fasting Plasma Glucose 
level between 126 mg/dL and 150 mg/dL or/and 
Postprandial Plasma Glucose level between 200 mg/dL 
and 250 mg/dL or/and HbA1C level ≥6.5% and the 
participants had any symptom such as Utash Mufrit 
(Polydipsia), Kasrat al-Bawl (Polyuria), Kasrat  
al-Ishtiha (Polyphagia), Bawl Layli (Nocturia), I’ya 
(Fatigue), Naqs al-Wazn (Loss of Weight), Burning 
Sensation in palm and soles, Sadr (Giddiness), Naqs  
al-Shahwa (Loss of Libido)8-10. Participants having 
comorbid conditions such as blindness, ischemic heart 
disease, stroke and any hepato-renal dysfunction were 
not included in the study. Participants on Insulin 
therapy and those suffering from diabetes mellitus 
type-I, pregnant and lactating women were not part of 
the study. 
 
Sample size estimation 
The sample size for this study was estimated 
empirically to be 75 participants including 25% 
dropouts. The target sample size of this study was 60 
participants: 30 participants in test group (Group-A) 
and control group (Group- B) each. In total 242 
participants were screened but 159 participants did not 
fulfil the inclusion and exclusion criteria of the study. 
The remaining 83 participants were randomly allocated 
in test and control groups. Out of them, 8 participants 
from the test group and 12 participants from the control 
group were dropped out or discontinued from the study 
due to non-compliance of the therapy, lost to follow-
up, concurrent illness and migration of the participants. 
Moreover, three participants were withdrawn from the 
study after four weeks of treatment due to continuous 
rise in serum glucose level beyond the cut-off blood 
sugar level described in inclusion criteria of the study 
due to poor efficacy of the Unani formulation. It was 
observed that the number of participants dropped-out in 
this study was comparatively higher than expectation.  
 
Intervention 
Participants of group A were treated with the classical 
Unani formulation constituting of Gurmar Booti 
(Gymnema sylvestre), Gilo Khushk (Tinospora 
cordifolia) and Maghz-i-Tukhm Jamun (Syzygium 
cumini) as a test drug in the dosage form of the powder 
in the study. The test drug was given in a dosage of 6 g 
twice daily before 30 min of meal for 84 days. In the 
control group, allopathic drug metformin hydrochloride 
was given as standard drug in the dosage form of tablet 
in a dosage of 500 mg orally twice daily 30 min before 
meals. Each participant was advised to have a brisk walk 
of half an hour daily or 150 min / week and to take a diet 
as per the recommendation of the American Diabetes 
Association (ADA) guidelines12. 
 
Method of preparation of the drugs 
All the three ingredients of the Unani formulation 
were procured from the market in raw form. These 
ingredients were identified and authenticated by the 
botanist at the Survey of Medicinal Plants Unit (SMPU) 
of the institute. The specimens of these plant drugs were 
archived in the museum of the institute with the Voucher 
Specimen Numbers; Tinospora cordifolia (SMPU/CRI-
Hyd 13565), Syzygium cumini (SMPU/CRI-Hyd 13566), 
Gymnema sylvestre (SMPU/CRI-Hyd 13567). The 
formulation was prepared in the GMP certified 
pharmacy of the institute. All the ingredients in raw 
form were pulverized individually to make a fine 
powder. The powder form of all ingredients were mixed 
in the equal ratio (Table 1). Pouches of 168 g each were 
prepared for distribution to the participants.  
The participants fulfilling the inclusion and 
exclusion criteria were enrolled in the study after 
obtaining written informed consent form. Participants 




were given participant information sheets explaining 
thereby the rights of the participants before signing 
informed consent form. All the participants were 
recruited from Out Patient Department (OPD)/Indoor 
Patient Department (IPD) of Central Research Institute 
of Unani Medicine (CRIUM), Hyderabad and were 
randomly allocated into groups as per pre-specified 
block randomization scheme generated through a 
computer. The sequence of the block was concealed in 
envelopes. The data were recorded in case record form 
prepared for the study after a complete medical history, 
general, physical, systemic examination and 
investigation reports. Determination of temperament 
was done as per standardized questionnaire prepared by 
Central Council for Research in Unani Medicine 
(CCRUM), New Delhi, India11. The participants were 
followed-up for clinical evaluation at an interval of two 
weeks: 2,4,6,8,10,12 weeks. At each visit, participants 
were physically examined and fasting as well as 
postprandial serum glucose level was tested to monitor 
the blood glucose level. The compliance of the therapy 
was also recorded properly in case record form. 
 
Assessment of the efficacy of the drug 
The primary endpoint of the study was to maintain 
normoglyceamia at 12 weeks of treatment. The 
secondary endpoint was to measure a reduction in 
serum glucose at an interval of 14 days. The efficacy of 
the Unani formulation was assessed by measuring 
reduction in fasting plasma glucose (FPG) or 
postprandial plasma glucose (2 h PG) or decrease in 
HbA1c level by ≥1% and improvement in symptoms of 
Zayābīṭus Sukkari Qism Sāni (Diabetes Mellitus Type 2) 
on visual Analogue Scale (VAS) at 12 weeks of 
treatment comparing from baseline 
 
Assessment of Safety  
Safety and toxicity of the test drug was assessed on 
the basis of adverse effects (AEs) recorded at each 
follow-up visit (i.e., 2,4,6,8,10,12 weeks) and 
derangement of hepatic and renal function comparing 
at 12 weeks of treatment from baseline. 
 
Statistical analysis of the data 
The data collected were analysed as per protocol in 
this study. For primary outcome we performed non-
parametric analysis of variance (ANOVA) test to 
assess the difference between the two treatment groups. 
We also conducted paired sample t-test to compare the 
means from the same group at different times. A  
p-value of <0.05 was considered significant. Statistical 
analysis was performed using Graph Pad Prism 
statistical software (v5).  
 
Observations and Results 
A total of 60 participants completed the study. It was 
observed that participants had an average age 47.7 
years (both sexes), average weight 71.03 (±12.98) Kg, 
average BMI 28.05 (± 5.377) Kg/ square meter and 
average chronicity of 2.8 years (± 2.3) years at baseline 
were randomized into test group (n=30) and control 
group (n=30) (Fig. 1). It was also observed that 27 
participants (45%) belonged to the age group of 36-45 
Table 1 — Polyherbal Unani formulations 
Ingredients Quantity 
Gurmar Buti (Gymnema sylvestre) 4 g 
Gilo Khushk (Tinospora cordifolia) 4 g 
Maghz Tukhm-i -Jamun (Syzygium cumini Kernel seed) 4 g 
 
 
Fig. 1 — Distribution of participants according to sex & ages in both groups 




years. Out of 60 participants, 21 participants had 
Balghamī (Phlegmatic) temperaments. 60% of the 
participants were male among them. It was observed 
that the participants presented with the symptoms 
polyuria, polydipsia, loss of libido and burning 
sensation in palm and soles. In this study, the test drug 
showed better improvement in Utash Mufrit 
(Polydipsia), Kasrat al-Bawl (Polyuria), Kasrat  
al-Ishtiha (Polyphagia), Bawl Layli (Nocturia), 
I’ya(Fatigue), burning sensation in palm and soles and 
Naqs al-Shahwa (Loss of Libido) in comparison to 
control drug (Table 2 & Table 3).  
In this study efficacy of the formulation was 
assessed in terms of reduction in fasting, postprandial 
serum glucose and glycosylated hemoglobin in blood 
at 12 weeks of treatment in comparison to base line. In 
the test group, mean fasting blood glucose was 
147.4±5.45 mg/dL at base line whereas it was 
157.5±9.03 mg/dL in the control group. At the end of 
the study, mean fasting blood glucose was reduced to 
116.1±5.05 mg/dL and 141.7±6.9 mg/dL in test group 
and control group respectively (Table 4). The result 
showed that a reduction in mean fasting blood glucose 
was higher in test group at 12 weeks of treatment.  
The result showed that in test group, mean 
postprandial blood glucose was less than that of control 
group at baseline. This study revealed that in the test 
group , mean postprandial blood glucose was reduced 
to 185.9±8.9 mg/dL from 225.5±7.3 mg/dL at the end 
of the study. But in the control group, reduction in 
mean postprandial blood glucose was slightly higher. 
The mean postprandial blood glucose came down in 
the control group 141.7±6.9 mg/dL from 239.64±10.9 
mg/dL (Table 5). This study concluded that the study 
drug was non-inferior to the control drug. When mean 
HbA1c in both groups was compared, the difference in 
the mean HbA1c between test and control groups was 
significant (p<0.05). The mean HbA1c (%) in test and 
control groups at baseline was 8.33±0.2833 and 
8.28±0.3402 whereas at the end of 12 weeks of study 
the level of glycated haemoglobin in test and control 
Table 4 — Effect on fasting blood glucose (FBG), (Mean ±SEM) 





























Note: F.U.- Follow-Up 




BT  AT 
No. of  
Pts. 
% of  
Pts. 
No. of  
Pts. 
% of  
Pts. 
Polyurea Present 19 63.33 02 6.67 
Absent 11 36.67 28 93.34 
Polydipsia Present 25 83.34 07 6.67 
Absent 05 16.67 23 93.34 
Polyphagia Present 14 46.67 20 66.67 
Absent 16 53.34 10 33.34 
Nocturia Present 14 46.67 05 16.67 
Absent 16 53.67 25 83.34 
Fatigue Present 18 60 08 26.67 
Absent 12 40 22 73.34 
Loss of Wt. Present 02 6.67 00 00 
Absent 28 93.34 30 100 
Giddiness Present 04 13.34 04 13.34 
Absent 26 86.67 26 86.67 
Loss of libido Present 07 23.34 04 13.34 
Absent 23 76.67 26 86.67 
Burning sensation in 
Palm & Sole 
Present 18 60 05 16.67 
Absent 12 40 25 83.34 













Polyuria Present 22 73.34 09 30 
Absent 08 26.67 21 70 
Polydipsia Present 26 86.67 05 16.67 
Absent 04 13.34 25 83.34 
Polyphagia Present 18 60 03 10 
Absent 12 40 27 90 
Nocturia Present 18 60 08 26.67 
Absent 12 40 22 73.34 
Fatigue Present 20 66.67 11 36.67 
Absent 10 33.34 19 63.33 
Loss of Weight Present 05 16.67 27 90 
Absent 25 83.34 03 10 
Giddiness Present 07 23.34 02 6.67 
Absent 23 76.67 28 93.34 
Loss of libido Present 08 26.67 08 26.67 
Absent 22 73.34 22 73.34 
Burning sensation in 
Palm & Sole 
Present 18 60 08 26.67 
Absent 12 40 22 73.34 




groups was reduced to 7.303±0.2627 and 7.153 
±0.2553 respectively (Table 6).  
 
Discussion 
This prospective study compared glycemic control, 
clinical outcome and amelioration of subjective 
symptoms in participants with diabetes mellitus type  
2 treated with a Unani formulation in group-A and 
metformin hydrochloride in group-B participants. We 
observed that both treatments resulted in sustained 
improvement in glycemic control. During the study 
event of hypoglycemia was not observed in both the 
groups. It was also observed that primary outcome to 
maintain normoglyceamia at 12 weeks of treatment 
was found significant. The Unani formulation showed 
efficacy in terms of reduction in serum glucose at  
12 weeks of treatment. The possible mechanism of 
action of the Unani formulation to act as 
hypoglycemic and ameliorative to the symptoms may 
be hypothesized. The Unani formulation constituted 
of three herbal medicines having anti-diabetic 
activities may be acted synergistically to control and 
maintain normoglycaemia. The Unani formulation 
might be responsible for the secretion of insulin in 
required quantity from the beta cells of the 
pancreas13,14. It might also be possible that the Unani 
formulation causes to lessen insulin resistance to 
tissue and thereby control serum glucose level. The 
ingredient T. cordifolia increases the activity of the 
glycogen synthase in liver and also increases the 
storage of glucose in hepatocytes15. The biologically 
active component of S. cumini, Jamboline also 
possesses glucose lowering effect13. Presence of 
gymnemic acid in G. sylvestre also produces 
hypoglycemia16. Moreover, these plants possess 
antioxidant, hypolipidemic and hepatoprotective 
properties which help in amelioration of subjective 
symptoms of the participants13,14. 
Metformin is a known potential oral hypoglycemic 
and is first-line medication to manage diabetes 
mellitus type 2. Jennifer A Hirst reported that 
metformin monotherapy lowered HbA1C by 1.12% 
and this effect was sustained at 24 weeks17. 
This study had several limitations. The sample size 
was very small and the duration of protocol therapy 
was also very short. The duration of the study was 
limited to two years due to academic restrictions. The 
participants, therefore, could not be followed for a 
long time in the post-trial period. 
The Unani formulation was found safe and showed 
no adverse effect. Haemoglobin per cent, RBC count, 
total leucocyte counts, differential leucocyte counts, 
platelets counts, liver function tests (S. Bilirubin, 
SGOT, SGPT, ALP) and kidney function tests  
(S. Creatinine, S.Urea) were within normal limits at 
12 weeks of treatment. 
 
Conclusion 
DM Type 2 is prevalent in India and other 
neighbouring countries. Its rising incidence and 
prevalence become a burden for the nation. Oral 
hypoglycaemics are not capable to deal with DM Type 
2. In this study, an attempt was made to test the efficacy 
of the Unani formulation in DM Type 2 participants 
with an intent to treat concept in search of an effective, 
cheap and comparatively better medicine. This study 
showed that the Unani formulation reduced 20% fasting 
blood glucose and 17% postprandial blood glucose level 
at 12 weeks of treatment in the majority of the 
participants. The results also showed that the Unani 
formulation was non-inferior to active control drug 
metformin hydrochloride. Althoughthe study was 
conducted with a single fixed dose of the Unani 
formulation. For a better understanding of the efficacy of 
the Unani formulation, multiple-dose studies may be 
conducted with a large sample size and longer duration 
of the study. The Unani formulation was tolerated well 
and showed no systemic toxicity. This Unani 
formulation was constituted of herbal drugs having 
hypoglycemic activities. This study was the first attempt 
to study the safety and efficacy of the Unani formulation 
on scientific parameters. It may be suggested that 
maximum therapeutic dosage, pharmacokinetics and 
pharmacodynamics of the Unani formulation may be 
studied in near future. A clinical trial may be also 
Table 6 — Effect on HbA1c % (Mean ±SEM) 
Group Assessment HbA1c on base line and 6th follow-
Up 
 Base Line 6th F.U. 
Test 8.330±0.2833 7.303±0.2627 
Control 8.28±0.3402 7.153 ±0.2553 
 
Table 5 — Effect on post prandial blood glucose (PPBG) (Mean ±SEM) 
Groups B.L. 1st F.U. 2nd F.U. 3rd F.U. 4th F.U. 5th F.U. 6th F.U. 
Test 225.5±7.375 255.7±17.86 253.6±13.98 242.3±18.37 251.2±18.74 240.8±19.24 185.9±8.966 
Control 239.64±10.9 222.16±16.5 231.8±13.07 220.5±15.2 228.76±14.8 209.93±12.7 141.7±6.9 
 




conducted with a large sample size to establish its 
efficacy in reducing serum glucose.  
 
Acknowledgement 
We are thankful to Prof Asim Ali Khan, Director 
General of Central Council for Research in Unani 
Medicine, New Delhi for his assistance and kind support. 
 
Conflict of Interest 
None 
 
Contribution of the authors 
N A conducted this clinical study, collected the data 
and drafted this manuscript. M N supervised this study 
and edited the manuscript. S H F conducted laboratory 
investigations. M H K vetted the manuscript and 
provided technical support during the study. 
 
References 
1 Anonymous, GBD 2015 Risk Factors Collaborators. Global, 
regional, and national comparative risk assessment of 
behavioural, environmental and occupational, and metabolic 
risks or clusters of risks, 1990-2015: a systematic analysis for 
the Global Burden of Disease Study 2015, Lancet, (388) 
(2016) 1659-1724. doi: 10.1016/S0140-6736(16)31679-8 
2 Anonymous, IDF Diabetes Atlas 2017, (International Diabetes 
Federation, Belgium), 2017, 42. https://www.diabetesatlas.org 
/upload/resources/previous/files/8/IDF_DA_8e-EN-final.pdf 
3 Anonymous, IDF Diabetes Atlas 2017, (International Diabetes 
Federation, Belgium), 2017, 16. 
4 De Fronzo R A, Ferrannini E, Zimmet P & George M K, 
Alberti M, International Textbook of Diabetes Mellitus, 4thed 
(2) (Wiley-Blackwell, USA) 2015, 03. 
5 Anonymous, IDF Diabetes Atlas 2017, (International Diabetes 
Federation, Belgium), 2017, 43-47. 
6 Anonymous, IDF Diabetes Atlas 2017, (International Diabetes 
Federation, Belgium), 2017, 52. 
7 Kabiruddin M. Bayaz-e-Kabir, 5th ed. Vol 1, (Hikmat Book 
Depot, Hyderabad), 1935, 177-179. 
8 Anonymous, Classification and diagnosis of diabetes: 
Standards of Medical Care in Diabetes- 2018. Diabetes Care 
2018; 41 (Suppl. 1): S13–S27. https://doi.org/10.2337/dc18-
S002 
9 Jameson, Fauci A S, Kasper, Hauser, Longo et al., Harrison’s 
Principles of Internal Medicine, 19th ed, Vol 2 (McGraw Hill, 
USA), 2015, 2399-2420. 
10 Chandalia H B, Sridhar G R, Das A K, Madhu S V & Mohan 
V, et al, RSSDI Textbook of Diabetes Mellitus, (3rd ed), 
(Jaypee Brothers Medical Publishers (P) Ltd, New Delhi), 
2014, 367-371. 
11 Naaz F, Mastan A, Abid M & Khan N, Clinical Evaluation of 
Mizaj (Temperament) of the Subjects of Pelvic inflammatory 
disease, World J Pharm Res, 5 (8) (2016) 713-728. 
12 Anonymous, Prevention or delay of Type 2 diabetes: 
Standards of Medical Care in Diabetes- 2018. Diabetes Care 
2018; 41 (Suppl. 1): S51–S54. https://doi.org/10.2337/dc18-
S005 
13 Ahmad N, Nawab M & Kazmi M H, Medicinal Potential of 
Jamun (Syzygium cumini L), A Review, Journal of Drug 
Delivery and Therapeutics, 9 (5) (2019) 175-180. 
https://doi.org/10.22270/jddt.v9i5.3568 
14 Ahmad N, Nawab M & Qamar-Uddin, Medicinal Properties of 
Gilo (Tinospora cordifolia) - A Review, World J Phar Pharm 
Sci; 8 (8) (2019) 430-440. 
15 Puranic N & Devi S Anti-diabetic activity of Tinospora 
cordifolia in streptozocin diabetic rats, does it act like 
sulfonylurea, Turk J Med Sci, 40 (2) (2010) 265-270. 
16 Sugihara Y, Nojima H, Matsuda H, Murakami T & Yoshikawa 
M, et al, Antihyperglycemic effects of gymnemic acid IV, a 
compound derived from Gymnema sylvestre leaves in 
streptozotocin diabetic mice, J Asian Nat Prod Res, (2) (2000) 
321–7. https://doi.org/10.1080/10286020008041372 
17 Hirst J A, Farmer A J, Ali R, Roberts N W & Stevens R J, 
Quantifying the effect of metformin treatment and dose on 
glycaemic control, Diabetes Care, (35) (2012) 446-454. 
https://doi.org/10.2337/dc11-1465 
 
